Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2023-10-30 Major Shareholding Noti…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required when an entity or individual acquires a significant stake (typically 5% or more) in a publicly traded company, or when there is a change in such holdings. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2023-10-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a mandatory disclosure for major shareholders or executives when their shareholding changes, which falls under the category of 'Director's Dealing' (DIRS) as it reports insider/major shareholder transactions.
2023-10-27 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(호흡기세포융합바이러스 (Respiratory Syncytial Virus, RSV) 예방 백신 (EuRSV, 유알에스브이)의 제1상 국내 임상시험계획승인 신청(IND))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eubiologics regarding the submission of an Investigational New Drug (IND) application for a Phase 1 clinical trial of an RSV vaccine. It follows the standard format for 'Major Management Matters' (주요경영사항) in the Korean stock market (KOSDAQ/KOSPI), which is used to disclose material events such as clinical trial applications. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2023-10-10 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Eubiologics regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) with UNICEF. It details the contract value, duration, and terms. Since this is a specific regulatory announcement of a material business event (a contract award) that does not fit into categories like financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2023-10-04 Korean
투자판단관련주요경영사항(EuMCV4주 (수막구균 단백 접합 백신) 기술이전 계약 체결)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Eubiologics regarding a technology transfer agreement for a meningococcal conjugate vaccine with LLC Nanolek. It details the contract terms, milestones, and financial impact. Since this is a specific corporate event announcement regarding a business agreement (licensing/technology transfer) rather than a periodic report, dividend notice, or management change, it falls under the 'Regulatory Filings' category as a general corporate disclosure.
2023-09-21 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling of an Investor Relations (IR) meeting. It provides details such as the date, location, purpose, and participants of the meeting. Since it is an announcement of an upcoming event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a general regulatory filing/announcement.
2023-08-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.